To some extent, such efforts have already begun with the development of therapies aiming to ameliorate α-synuclein aggregation, albeit in the context of PD, such as prasinezumab; however, this therapy has not shown meaningful benefits in a Phase II clinical trial beyond an exploratory analysis in a post-hoc sub-group analysis [104, 105]. Here, SNCA is linked to Parkinson disease.